Evidence map›Paper›PMID 28078223›Full record

ReviewTranslational andrology and urology2016

Testosterone therapy and prostate cancer.

Alexander W Pastuszak, Katherine M Rodriguez, Taylor M Nguyen, Mohit Khera

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational andrology and urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Testosterone and prostate health: Have the paradigms truly shifted?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Article
  7. Review
  8. Article
  9. Review
  10. The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis.International braz j urol : official journal of the Brazilian Society of Urology
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alexander W PastuszakCenter for Reproductive Medicine, Baylor College of Medicine, Houston, TX, USA;; Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Katherine M RodriguezBaylor College of Medicine, Houston, TX, USA.
Taylor M NguyenBaylor College of Medicine, Houston, TX, USA.
Mohit KheraScott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of exogenous testosterone to treat hypogonadism in the men with a history of prostate cancer (CaP) remains controversial due to fears of cancer recurrence or progression. Due to the detrimental impact of hypogonadism on patient quality of life, recent work has examined the safety of testosterone therapy (TTh) in men with a history of CaP. In this review, we evaluate the literature with regards to the safety of TTh in men with a history of CaP. TTh results in improvements in quality of life with little evidence of biochemical recurrence or progression in men with a history of CaP, or

Indexed as

hormone replacementHypogonadismprostate cancer (CaP)prostatectomyradiation therapytestosterone

Identifiers

PMID28078223
PMCPMC5182214
OpenAlexW2526821115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.